227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIALR. Merryman, Yazeed Sawalha, Rosario Tringale et al.|Hematological Oncology|2025Cited by 1
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trialReid W. Merryman, Yazeed Sawalha, Danielle Wallace et al.|Blood|2025Cited by 0